The company said Aetos Stemless addresses the growing demand for anatomical total shoulder replacement with a small operating room footprint, enabling an efficient procedure. Smith+Nephew designed it to maximize metaphyseal fixation and stability. It has an inlay collar, cruciate fins and porous titanium coating to encourage biological fixation.
Earlier this year, Smith+Nephew fully launched its Aetos shoulder system in the U.S. with additional FDA clearances. Aetos originally received FDA clearance in June 2023, bolstering the company’s upper extremity portfolio. London-based Smith+Nephew designed Aetos to restore patients’ range of motion and help minimize arthritic shoulder pain. The system features the Aetos Meta Stem designed for maximizing stability preserving bone and maintaining patient anatomy.
The new stemless implant expands the portfolio, enabling streamlined convertibility from Stemless to Meta Stem.
“Aetos Stemless represents a significant advancement in shoulder arthroplasty, underscoring our commitment to superior patient outcomes and driving progress in the field of orthopaedic surgery. We are excited to continue unveiling future technologies that will reshape the treatment of shoulder conditions,” said Craig Gaffin, president of Global Orthopaedics for Smith+Nephew. “With Aetos Stemless, we’re now able to further personalize surgery, providing options that help surgeons give patients the best chance for recovery and a return to living their ‘Life Unlimited.’”
This represents positive news for the orthopedic giant, which recently enacted significant layoffs across the company.
